Agilent Technologies Shares Vision for Precision Genomics at ASHG 2015
October 07 2015 - 11:00AM
Business Wire
Agilent Technologies Inc. (NYSE:A) is sharing its vision for
precision medicine this week at the annual meeting of the American
Society of Human Genomics. The conference, held in Baltimore,
Maryland, is a forum for discussing recent advances in all areas of
human genetics.
“As new technologies and greater understanding of the causes and
pathways of diseases are moving through the research-clinical
continuum, they are driving a revolution in precision medicine—a
revolution that is enabling physicians to identify and treat
maladies earlier, more effectively and at a lower cost,” said
Herman Verrelst, Agilent vice president and general manager,
Genomics Solutions Division and Clinical Applications Division.
“Precision medicine requires precision genomics,” he said.
“Agilent is focusing its efforts on developing solutions for human
and reproductive genetics and cancer genetics. Our latest products,
which we are showcasing at ASHG, demonstrate how Agilent is
enabling clinical researchers to detect disease-associated genetic
changes faster, more cost-effectively and with confidence.”
A speaker at the conference, Verrelst noted that Agilent has
initiatives in place to develop products for single-cell and
liquid-biopsy analyses and is currently collaborating with key
laboratories. These initiatives, he said, will be important in
screening for and tracking genetic changes in reproductive and
cancer samples.
In addition, he said, Agilent’s recent acquisition of Cartagenia
enhances its bioinformatics portfolio and provides customers with
access to clinical-grade data-interpretation support software to
visualize, assess and report clinical genetics data in the context
of patient information.
Building on a strong legacy and expertise within bioreagents,
automation and informatics, Agilent this week is showcasing a
number of innovative products to support clinical research:
- GenetiSure Pre-Screen kit for analysis
of single cells in embryos.
- OneSeq target enrichment for
genome-wide detection of copy number variations, loss of
heterozygosity and mutations—all in a single assay.
- HaloPlexHS target enrichment for
detecting rare variants (<1% allele frequency) using molecular
barcodes.
- SureSelect Human All Exon V6 for
targeting exons in even hard-to-capture regions.
- The AriaMx Real-Time PCR system for
amplifying, detecting and analyzing polymerase chain
reactions.
Agilent also is showcasing its Cartagenia Bench Lab NGS product
that provides interpretation support to identify and report on
clinically relevant variants in next-generation sequencing.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in
life sciences, diagnostics and applied chemical markets, is the
premier laboratory partner for a better world. Agilent works with
customers in more than 100 countries, providing instruments,
software, services and consumables for the entire laboratory
workflow. The company generated revenues of $4.0 billion in fiscal
2014 and employs about 12,000 people worldwide. Agilent marks its
50th anniversary in analytical instrumentation this year.
Information about Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and
executive news is available at www.agilent.com/go/news.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151007005229/en/
Agilent Technologies Inc.Victoria Wadsworth-Hansen, +1
408-553-2005victoria.wadsworth-hansen@agilent.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024